Unknown

Dataset Information

Serum myostatin as a candidate disease severity and progression biomarker of spinal muscular atrophy.


ABSTRACT: The identification of biomarkers for spinal muscular atrophy is crucial for predicting disease progression, severity, and response to new disease-modifying therapies. This study aimed to investigate the role of serum levels of myostatin and follistatin as biomarkers for spinal muscular atrophy, considering muscle atrophy secondary to denervation as the main clinical manifestation of the disease. The study evaluated the differential gene expression of myostatin and follistatin in a lesional model of gastrocnemius denervation in mice, as well as in a meta-analysis of three datasets in transgenic mice models of spinal muscular atrophy, and in two studies involving humans with spinal muscular atrophy. Subsequently, a case-control study involving 27 spinal muscular atrophy patients and 2

SUBMITTER: de Albuquerque ALA 

PROVIDER: S-EPMC10939446 | biostudies-literature | 2024

REPOSITORIES: biostudies-literature